摘要
目的总结程序性死亡受体-1(PD-1)/程序性死亡配体-1(PD-L1)抑制剂及其联合治疗在结直肠癌中的研究进展并为结直肠癌提供新的治疗方向。方法收集近年来PD-1/PD-L1抑制剂在结直肠癌中应用的研究进展的相关文献并进行综述。结果针对PD-1/PD-L1通路的抗体在结直肠癌患者的临床试验中取得了一定的研究成果,尤其是在高频微卫星不稳定患者中效果更佳,多种抗体联合治疗以及其与化疗、靶向治疗联合应用方案具有更好的生存获益。结论 PD-1/PD-L1抑制剂在高频微卫星不稳定结直肠癌生存获益方面具有一定疗效,尤其是联合方案显示出更好的效果。
Objective To summarize research progress on programmed death 1 (PD-1) and programmed deathligand 1 (PD-L1) inhibitors and their combination therapies in colorectal cancer and to provide a new treatment direction for colorectal cancer. Method The relevant literatures on the application of the PD-1/PD-L1 inhibitors in the colorectal cancer in recent years were collected and reviewed. Results The clinical trials of anti-PD-1/PD-L1 signaling pathway antibodies had made some achievements in the colorectal cancer, especially in the patients with high frequency microsatellite instability. And the combination therapy of multiple antibodies and the combination with chemotherapy and targeted therapies were more effective. Conclusion PD-1/PD-L1 inhibitors have some certain curative effects on survival of colorectal cancer with high frequency microsatellite instability, especially combination shows a better effect.
作者
刘恩瑞
王贵玉
LIU Enrui;WANG Guiyu(Department of Colorectal Cancer Surgery,The Second Affiliated Hospital of Harbin Medical University,Harbin 150086,P. R. China)
出处
《中国普外基础与临床杂志》
CAS
2019年第5期620-624,共5页
Chinese Journal of Bases and Clinics In General Surgery
基金
吴阶平医学基金会临床科研专项资助基金(项目编号:320.6750.15183)
